Yi‐Long Wu - Researcher Profile | RDL Research Database

Publications

3 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim , Vera Hirsh , Tony Mok +15 more

2008 The Lancet 1240 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok , Yi‐Long Wu , Sumitra Thongprasert +16 more

Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the t...

2009 New England Journal of Medicine 8112 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 12,527
Institution: Guangdong Provincial People's Hospital

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-3611-0258

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.